Dr. Nikki Delk received $789,000 from the the American Cancer Society for her research on IL-1-p62 Axis Regulation and Function in Castration Resistant PCa. The study identified how an inflammatory cytokine, interleukin-1 (IL-1), alters cancer cells to promote tumor progression. Dr. Delk and her lab’s data supports that IL-1 reprograms AR+ PCa cells to mimic AR PCa gene expression patterns that favor AR-targeted treatment resistance and cell survival.